FLOW: The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor Agonist

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

By AdventHealth FEATURING Richard Pratley

September 17, 2024

Feat. B. Hirsch

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

ACC 2023 Conference Coverage

A. Armbruster

ASPC 2019 Congress on CVD Prevention

Robert Busch

Cardiometabolic Health Congress (CMHC)

Springer Healthcare IME

S. Seidu, B. Itzhak, M. Ungan, L. Moist

Matilde Ladnier

Diana Isaacs

Houston Methodist

T. R. Mccarty

Michigan Medicine

Diana Isaacs

Patricia Kao

ASN Kidney Week 2024 Highlights

Login

Login

Join VuMedi

FLOW: The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor Agonist

A Journey through Five Phase 3 Clinical Trials for a T2D Incretin Me…

Initiating and Monitoring Patients on a Non-Statin Lipid-Lowering Th…

Recommended

What Does Elevated Troponin Mean in COVID-19?

Primer on Diabetes Management

ACC 2023: SGLT2i Use - Dos and Don'ts

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Labs to Check on Semaglutide or Tirzepatide

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

CKD in Primary Care Full Webinar

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Phosphorus Management: P-Binders, Diet, Etc.

Weightloss in Menopause

Tirzepatide Updates

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Incretin-based Therapies in the Management of Obesity and its Comorb…

The Differences Between the Products of GLP1's and GLP/GIPs

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Tirzepatide for Type 2 Diabetes

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

IgA Nephropathy Highlights from ASN Kidney Week 2024